Adverse events following immunization with mRNA and viral vector vaccines in individuals with previous severe acute respiratory syndrome coronavirus 2 infection from the Canadian National Vaccine Safety Network

Bettinger, Julie A.; Shulha, Hennady P.; Valiquette, Louis; Muller, Matthew P.; Vanderkooi, Otto G.; Kellner, James D.; Top, Karina A.; Sadarangani, Manish; McGeer, Allison; Isenor, Jennifer E.; Marty, Kimberly; Soe, Phyumar; De Serres, Gaston; Canadian Immunization Research Network; Irvine, Michael A.

doi:https://open-science.canada.ca/handle/123456789/3386

Adverse events following immunization with mRNA and viral vector vaccines in individuals with previous severe acute respiratory syndrome coronavirus 2 infection from the Canadian National Vaccine Safety Network

Simple item page

Full item details

dc.contributor.author: Bettinger, Julie A.; Shulha, Hennady P.; Valiquette, Louis; Muller, Matthew P.; Vanderkooi, Otto G.; Kellner, James D.; Top, Karina A.; Sadarangani, Manish; McGeer, Allison; Isenor, Jennifer E.; Marty, Kimberly; Soe, Phyumar; De Serres, Gaston; Canadian Immunization Research Network; Irvine, Michael A.
dc.date.accessioned: 2025-01-31T20:24:32Z
dc.date.available: 2025-01-31T20:24:32Z
dc.date.issued: 2022-10-31
dc.description.abstract - en: Background Adults previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) develop short-term immunity and may have increased reactogenicity to coronavirus disease 2019 (COVID-19) vaccines. This prospective, multicenter, active-surveillance cohort study examined the short-term safety of COVID-19 vaccines in adults with a prior history of SARS-CoV-2. Methods Canadian adults vaccinated between 22 December 2020 and 27 November 2021 were sent an electronic questionnaire 7 days post–dose 1, dose 2, and dose 3 vaccination. The main outcome was health events occurring in the first 7 days after each vaccination that prevented daily activities, resulted in work absenteeism, or required a medical consultation, including hospitalization. Results Among 684 998 vaccinated individuals, 2.6% (18 127/684 998) reported a prior history of SARS-CoV-2 infection a median of 4 (interquartile range: 2–6) months previously. After dose 1, individuals with moderate (bedridden) to severe (hospitalized) COVID-19 who received BNT162b2, mRNA-1273, or ChAdox1-S vaccines had higher odds of a health event preventing daily activities, resulting in work absenteeism or requiring medical consultation (adjusted odds ratio [95% confidence interval]: 3.96 [3.67–4.28] for BNT162b2, 5.01 [4.57–5.50] for mRNA-1273, and 1.84 [1.54–2.20] for ChAdox1-S compared with no infection). Following dose 2 and 3, the greater risk associated with previous infection was also present but was attenuated compared with dose 1. For all doses, the association was lower or absent after mild or asymptomatic infection. Conclusions Adults with moderate or severe previous SARS-CoV-2 infection were more likely to have a health event sufficient to impact routine activities or require medical assessment in the week following each vaccine dose.
dc.description.sponsorship: This work was supported by the COVID-19 Vaccine Readiness funding from the Canadian Institutes of Health Research and the Public Health Agency of Canada CANVAS grant number CVV-450980 and the Public Health Agency of Canada, through the Vaccine Surveillance Reference Group and the COVID-19 Immunity Task Force (reported by M. A. I., J. E. I., G. D. S., M. S., J. A. B., J. D. K., O. G. V., K. A. T., K. M., L. V., M. P. M., and P. S.). G. D. S. reports support from the Ministère de la Santé et des Services Sociaux du Quebec. M. S. is supported via salary awards from the BC Children's Hospital Foundation and the Michael Smith Foundation for Health Research.
dc.identifier.doi: https://doi.org/10.1093/cid/ciac852
dc.identifier.issn: 1537-6591
dc.identifier.pubmedID: 36310514
dc.identifier.uri: https://open-science.canada.ca/handle/123456789/3386
dc.language.iso: en
dc.publisher - en: Oxford University Press on behalf of Infectious Diseases Society of America
dc.rights - en: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
dc.rights - fr: Creative Commons Attribution - Pas d'utilisation commerciale - Pas de modification 4.0 International (CC BY-NC-ND 4.0)
dc.rights.uri - en: https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.uri - fr: https://creativecommons.org/licenses/by-nc-nd/4.0/deed.fr
dc.subject - en: Health; Coronavirus diseases; Immunization; Epidemiology
dc.subject - fr: Santé; Maladie à coronavirus; Immunisation; Épidémiologie
dc.subject.en - en: Health; Coronavirus diseases; Immunization; Epidemiology
dc.subject.fr - fr: Santé; Maladie à coronavirus; Immunisation; Épidémiologie
dc.title - en: Adverse events following immunization with mRNA and viral vector vaccines in individuals with previous severe acute respiratory syndrome coronavirus 2 infection from the Canadian National Vaccine Safety Network
dc.type - en: Article
dc.type - fr: Article
local.article.journalissue: 6
local.article.journaltitle - en: Clinical Infectious Diseases
local.article.journalvolume: 76
local.pagination: 1088-1102
local.peerreview - en: Yes
local.peerreview - fr: Oui

Download(s)

Original bundle

Now showing 1 - 1 of 1

Name: bettinger-adverse-events-mrna-viral-vector-vaccines-severe-acute-respiratory-syndrome-coronavirus-2.pdf

Size: 740.85 KB

Format: PDF

Download file

Collection(s)

Communicable diseases